Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis.
Tumour necrosis factor (TNF) is a proinflammatory cytokine that is known to regulate inflammation in a number of autoimmune diseases, including multiple sclerosis (MS). Although targeting of TNF in models of MS has been successful, the pathological role of TNF in MS remains unclear due to clinical t...
Main Authors: | Sarah K Williams, Olaf Maier, Roman Fischer, Richard Fairless, Sonja Hochmeister, Aleksandar Stojic, Lara Pick, Doreen Haar, Sylvia Musiol, Maria K Storch, Klaus Pfizenmaier, Ricarda Diem |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3938650?pdf=render |
Similar Items
-
Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis
by: Sarah K. Williams, et al.
Published: (2018-09-01) -
The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation
by: Fabian Richter, et al.
Published: (2021-07-01) -
Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy
by: Roman Fischer, et al.
Published: (2015-03-01) -
Calcium-Binding Proteins as Determinants of Central Nervous System Neuronal Vulnerability to Disease
by: Richard Fairless, et al.
Published: (2019-04-01) -
TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages
by: Harald Wajant, et al.
Published: (2019-05-01)